Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Genedrive PLC (AIM:GDR) AIHL test preliminary recommendation by NICE
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
RNS Hotlist with Zak Mir: NANO, MXC, ITX, LVCG, QBIT, MEN & BBSN via Vox Markets
Nanoco Group (NANO), a specialist in the development and manufacture of cadmium-free quantum dots, announced the final agreements have been signed to settle the litigation with Samsung on a no
Novacyt S.A. (AIM:NCYT) DHSC Claim update – Trial date listed
Paris, France and Eastleigh, UK – 30 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt
RNS Hotlist with Zak Mir: HUI, ALK, POLB, HEMO, EML, MMAG, BVC, COBR, MBT, DVRG, BZT, KEFI, ATOM, OSI, ROQ, MEN & NCCL
Hydrogen Utopia International (HUI), a company specialising in turning non-recyclable mixed waste plastic into carbon-free fuels, announced the admission of its shares today at 8am to the Official List of
RNS Hotlist with Zak Mir: HUI, CTL, LVCG, AGL, REAT, GWMO, MEN & STK via Vox Markets
It would appear that it is take two as far as Hydrogen Utopia International (HUI)’s move to the standard list of the LSE. The company specialising in turning waste plastic
Novacyt S.A. (AIM:NCYT) Approval of genesig COVID-19 3G PCR test in UK
Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation
Novacyt S.A. (AIM:NCYT) UK Approval of genesig® SARS-CoV-2 Winterplex® 3G
A multiplex PCR test for the detection of winter viruses including SARS-CoV-2, influenza A and B, and RSV
Genedrive PLC (AIM:GDR) US FDA pre-submission for Genedrive MT-RNR1 kit
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
Genedrive PLC (AIM:GDR) NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for
Novacyt S.A. (AIM:NCYT) Launch of research-use-only adenovirus F41 assay
The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children